Janux Therapeutics, Inc.JANXNASDAQ

Revenue (LTM)

$10M

-5.6% YoY

Net Income (LTM)

$-114M

-64.7% YoY

Free Cash Flow

$-83M

Revenue CAGR (5Y)

—

Marginsdeclining

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	4	9↑136.8%	8↓6.1%	11↑31.0%	10↓5.6%
Gross Profit	4	8↑113.7%	6↓21.1%	9↑39.2%	8↓6.5%
Operating Income	-33	-67↓103.7%	-73↓8.8%	-99↓35.4%	-158↓59.5%
Net Income	-33	-63↓93.0%	-58↑7.6%	-69↓18.4%	-114↓64.7%
EBITDA	-33	-66↓101.9%	-71↓7.2%	-97↓36.3%	-112↓15.3%
EPS Diluted	-0.79	-1.52↓92.4%	-1.32↑13.2%	-1.28↑3.0%	-1.83↓43.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	36	51↑44.5%	19↓62.7%	431↑2142.2%	52↓87.8%
Total Current Assets	377	332↓11.8%	349↑5.1%	1,034↑196.0%	976↓5.6%
Total Assets	380	364↓4.2%	380↑4.5%	1,062↑179.0%	1,002↓5.6%
Total Current Liabilities	13	17↑29.0%	13↓21.0%	17↑34.0%	25↑43.2%
Total Liabilities	13	43↑220.6%	36↓16.7%	39↑7.4%	45↑15.5%
Total Equity	366	321↓12.4%	344↑7.4%	1,023↑197.0%	957↓6.4%
Total Debt	0	25↑12943.8%	25↓3.0%	23↓6.2%	22↓3.8%
Net Debt	-35	-26↑26.2%	5↑120.4%	-408↓7736.9%	-30↑92.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-17	-43↓152.8%	-51↓17.8%	-44↑13.4%	-82↓87.7%
Capital Expenditure	-1	-6↓334.9%	-2↑71.3%	-0↑80.6%	-1↓190.5%
Free Cash Flow	-18	-49↓167.5%	-52↓6.2%	-44↑15.7%	-83↓88.5%
Stock-Based Comp	7	17↑149.0%	20↑16.3%	33↑65.1%	0
Net Change in Cash	29	16↓44.6%	-32↓303.4%	411↑1376.8%	-378↓191.9%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance